Introducing the IDOV™ platform: utilizing oncolytic viruses to target & kill tumor cells with high specificity and efficacy.
Destroying cancer with a one-shot cure.
We have developed a “one-shot” cure for deadly cancers.
“The IDOV™ platform builds on past success with two prior generations of viruses that have been injected into hundreds of people worldwide.”
Dr. Nanhai George ChenChief Executive Officer, ViroMissile
Drug Candidates
Four patent-pending drug candidates with unique functions successfully developed and in preparation for IND filing.
IDOV-Stealth™
First-ever stealth oncolytic virus that survives well in blood and is resistant to be cleared by NK and T-cells.
IDOV-Safe™
First-ever “safety switch” to stop virus replication in healthy cells; 10× more effective against MSS CRC.
IDOV-Immune™
Enhances anti-tumor immunity, resulting in improved therapeutic efficacy.
IDOV-AntiAngio™
Inhibits tumor angiogenesis to further enhance the therapeutic effect of the oncolytic virus.